Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH: Bevacizumab-IRDye800CW in Soft Tissue Sarcoma
NCT03913806Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in soft tissue sarcoma (STS), sponsored by University Medical Center Groningen. Primary endpoint: Tracer detection up to 6 months. Started May 2018; status: completed.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03913806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913806.